SCHEMBL52115

SCHEMBL52115

COC(OC)c1ccc2c(=O)c3cc(C)ccc3sc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.43
KDM4E B2RXH2 3/20 0.43
NPC1 O15118 3/20 0.43
ALDH1A1 P00352 2/20 0.43
RAB9A P51151 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
HPGD P15428 2/20 0.39
POLB P06746 2/20 0.39
BCL2L1 Q07817 1/20 0.35
MCL1 Q07820 1/20 0.35
TP53 P04637 3/20 0.34
THRB P10828 2/20 0.33
USP2 O75604 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
LMNA P02545 1/20 0.32
MEN1 O00255 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29590308 1.00 MAPT (0.43) MAPTKDM4ENPC1ALDH1A1RAB9A
SCHEMBL16622747 0.84 KDM4E (0.41) MAPTKDM4ENPC1ALDH1A1RAB9A
SCHEMBL14985633 0.82 ALDH1A1 (0.50) MAPTKDM4ENPC1ALDH1A1RAB9A
SCHEMBL9980171 0.78 KDM4E (0.41) MAPTKDM4ENPC1ALDH1A1RAB9A
SCHEMBL1609870 0.78 KDM4E (0.51) MAPTKDM4ENPC1ALDH1A1RAB9A
SCHEMBL11158837 0.75 MPI (0.46) MAPTKDM4ENPC1ALDH1A1RAB9A
SCHEMBL12748045 0.75 KDM4E (0.61) MAPTKDM4ENPC1ALDH1A1RAB9A
SCHEMBL13971125 0.75 BCL2L1 (0.49) MAPTKDM4ENPC1ALDH1A1RAB9A
SCHEMBL2705508 0.74 KDM4E (0.44) MAPTKDM4ENPC1ALDH1A1RAB9A
SCHEMBL4541593 0.74 CMA1 (0.48) MAPTKDM4ENPC1ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 815 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11382868-B2 Transdermal UV-curable hydrogel resin, hydrogel curing the same and cataplasm containing the same ICURE PHARMACEUTICAL INC. (KR) 2022-07-12 US claimed
CN-107652222-B Oxime ester photoinitiators 巴斯夫欧洲公司 2021-09-10 CN claimed
US-10919909-B2 Photoinitiated reactions LINTFIELD LIMITED (GB) 2021-02-16 US claimed
US-20190211031-A1 PHOTOINITIATED REACTIONS LINTFIELD LIMITED (GB) 2019-07-11 US claimed
US-20190046463-A1 ULTRAVIOLET-HARDENING HYDROGEL RESIN AND HYDROGEL FOR TRANSDERMAL ADMINISTRATION, AND CATAPLASM AGENT CONTAINING SAME ICURE PHARMACEUTICAL INC. (KR) 2019-02-14 US claimed
EP-3415141-A1 ULTRAVIOLET-HARDENING HYDROGEL RESIN AND HYDROGEL FOR TRANSDERMAL ADMINISTRATION, AND CATAPLASM AGENT CONTAINING SAME Icure Pharmaceutical Inc. (KR) 2018-12-19 EP claimed
CN-101802022-B Photoinitiators for energy curing LAMBERTI SPA 2013-03-27 CN claimed
EP-2190887-B1 PHOTOINITIATORS FOR ENERGY CURING LAMBERTI SPA (IT) 2011-05-04 EP claimed
CN-101802022-A Photoinitiators for energy curing LAMBERTI SPA 2010-08-11 CN claimed
US-20100196826-A1 Photoinitiators for Energy Curing LAMBERTI SPA (IT) 2010-08-05 US claimed
EP-2190887-A1 PHOTOINITIATORS FOR ENERGY CURING Lamberti Spa (IT) 2010-06-02 EP claimed
US-20100093883-A1 Hydroxamic Esters as Photoinitiators LAMBERTI SPA (IT) 2010-04-15 US claimed
EP-2121323-A1 HYDROXAMIC ESTERS AS PHOTOINITIATORS Lamberti Spa (IT) 2009-11-25 EP claimed
WO-2009037130-A1 PHOTOINITIATORS FOR ENERGY CURING LAMBERTI SPA (IT) 2009-03-26 WO claimed
WO-2008104436-A1 HYDROXAMIC ESTERS AS PHOTOINITIATORS LAMBERTI SPA (IT) 2008-09-04 WO claimed
US-12637600-B2 Photocurable composition, cured product of same, photofusible resin composition and adhesive set RESONAC CORPORATION (JP) 2026-05-26 US disclosed
US-20260132243-A1 THERMOSETTING COMPOSITION AND CURED PRODUCT THEREOF, PHOTOMELTABLE COMPOSITION, AND STRUCTURAL BODY PRODUCTION METHOD RESONAC CORP (JP) 2026-05-14 US disclosed
US-4992547-A Aminoaryl ketone photoinitiators CIBA-GEIGY CORPORATION (US) 1991-02-12 US disclosed
EP-0138754-B1 PHOTOCURABLE COMPOSITIONS CIBA-GEIGY AG (CH) 1988-05-25 EP disclosed
EP-0138754-A2 Photocurable compositions CIBA-GEIGY AG (CH) 1985-04-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12637600-B2 Photocurable composition, cured product of same, photofusible resin composition and adhesive set ESD, CDH1, ASH2L MAPT 2260/4885KDM4E 2247/4885NPC1 4105/4885
US-10919909-B2 Photoinitiated reactions KMO, DECR1, PPOX MAPT 1604/4885KDM4E 2292/4885NPC1 2000/4885
US-20100196826-A1 Photoinitiators for Energy Curing PPOX, ECPAS, PTGES MAPT 31/4885KDM4E 1954/4885NPC1 2288/4885
US-20190211031-A1 PHOTOINITIATED REACTIONS DOHH, PAH, DBH MAPT 1061/4885KDM4E 1292/4885NPC1 2594/4885
US-20260132243-A1 THERMOSETTING COMPOSITION AND CURED PRODUCT THEREOF, PHOTOMELTABLE COMPOSITION, AND STRUCTURAL BODY PRODUCTION METHOD RER1, OXTR, MAP1LC3A MAPT 235/4885KDM4E 1812/4885NPC1 4792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.